MacroGenics Regains DART Asset As Takeda Narrows Focus
Executive Summary
MacroGenics has regained global rights to one of its DART compounds from Takeda, following a reprioritization of therapeutic areas by the Japanese firm that may open up new partnering opportunities in autoimmune disorders.